A Novartis sign hangs on the side of an office building in Cambridge, Massachusetts. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free ...
Novartis (NVS) Pharmaceuticals Canada said it is “extremely disappointed” that negotiations for Pluvicto, a treatment for patients with progressive PSMA-positive metastatic castration-resistant ...
On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu) vipivotide ...
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is ...
Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue ...
A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...
Novartis (NVS) Pharmaceuticals Canada announced the “successful conclusion” of negotiations with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Pluvicto. “While this is an ...
Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...
Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback